Ιδέ Παρακάτω

1.     Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. Buzzetti E, Hall A, Ekstedt M, Manuguerra R, Guerrero Misas M, Covelli C, Leandro G, Luong T, Kechagias S, Manesis EK, Pinzani M, Dhillon AP, Tsochatzis EA. Aliment Pharmacol Ther 2019;49:1214-1222.

2.     Metastatic Signet-Ring Cell Carcinoma of the Skin. Chrysanthos NV, Nezi V, Zafiropoulou R, Papatheodoridis G, Manesis E. Am J Gastroenterol 2018;113:1427.

3.     Assessment of biopsy-proven liver fibrosis by 2D-shear wave elastography: An individual patient data based meta-analysis. Herrmann E, de Lédinghen V, Cassinotto C, Chu WC, Leung VY, Ferraioli G, Filice C, Castera L, Vilgrain V, Ronot M, Dumortier J, Guibal A, Pol S, Trebicka J, Jansen C, Strassburg C, Zheng R, Zheng J, Francque S, Vanwolleghem T, Vonghia L, Manesis EK, Zoumpoulis P, Sporea I, Thiele M, Krag A, Cohen- Bacrie C, Criton A, Gay J, Deffieux T, Friedrich-Rust M. Hepatology 2018;67:260-272.

4.     Real-life cost of managing chronic HCV infection in Greece prior to Direct-Acting Antivirals (DAAs): an undeniable truth of spending more for less. Souliotis K, Siakavellas S, Golna C, Manesis E, Papatheodoridis G, Hatzakis A. Hippokratia 2018;22:127-131.

5.     Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. Kalafateli M, Zisimopoulos K, Vourli G, Rigamonti C, Goulis J, Manesis E, Manolakopoulos S, Tsochatzis E, Georgiou A, Diamantopoulou G, Thomopoulos K, Gogos C, Touloumi G, Akriviadis E, Lambropoulou-Karatza C, Triantos C. Dig Dis Sci. 2017;62:1363-1372.

6.     Impact of Safety-Related Dose Reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C cohort. Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. PLoS One 2016;11:e0151703.

7.     Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. Vourli G, Papatheodoridis G, Raptopoulou M, Dalekos GN, Hounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasilialdis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G, The HEPNET-Greece study. Hippokratia 2016;20:214-221.

8.     Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma. Fatourou E, Koskinas J, Karandrea D, Palaiologou M, Syminelaki T, Karanikolas M, Felekouras E, Antoniou E, Manesis EK, Delladetsima J, Tiniakos D. Eur J Gastroenterol Hepatol 2015;27:1094-102.

9.     Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou- Gigi M, Manesis E, Ketikoglou I, Dalekos G, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis I, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. Hippokratia 2014;18:57-64.

10.  Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; for the the HepNet.Greece Study Group. J Viral Hepat 201415. doi: 10.1111/jvh.12283. [Epub ahead of print] PubMed PMID: 25040685.

11.  Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou- Gigi M, Manesis E, Ketikoglou I, Dalekos G, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis I, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. Hippokratia 2014;18:57-64.

12.  Immigration, European Union and health issues: A commentary. Manesis EK. Dig Liver Dis 2014;46:25-6

13.  Changes of HBsAg and interferon-inducible protein 10 serum levels in naïve HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E. J Hepatol 2014;60:62-68.

14.  Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, Koutsounas S, Vafiadis I, Nikolopoulou G, Giannoulis G, Germanidis G, Papatheodoridis G, Touloumi G. J Hepatol 2013;59:949-56.

15.  Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine. Ntziora F, Paraskevis D, Haida C, Manesis E, Papatheodoridis G, Manolakopoulos S, Elefsiniotis I, Karamitros T, Vassilakis A, Hatzakis A. J Clin Microbiol 2013;51:2893-2900.

16.  Development and assessment of a novel real-time PCR assay for quantitation of hepatitis D virus RNA to study viral kinetics in chronic hepatitis D. Katsoulidou A, Manesis E, Rokka C, Issaris C, Pagoni A, Sypsa V, Hatzakis A. J Viral Hepat 2013;20:256-262.

17.  Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Manolakopoulos S, Striki A, Deutsch M, Mela M, Ketikoglou I, Tzourmakliotis D, Manesis EK, Papatheodoridis GV. Liver Int 2011;31:1525-1532.

18.  Effect of antiviral therapy on the immunohistochemical expression of bcl- xL and bax protein in patients with HBeAg-negative chronic hepatitis B. Cholongitas E, Papatheodoridis GV, Manesis EK, Petraki K, Tiniakos D, Hadziyannis SJ. J Med Virol 2011;83:1165-1171.

19.  Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou- Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group. Gut 2011;60:1109-1116.

20.  Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. J Hepatol. 2011;55:61-68.

21.  Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Manolakopoulos S, Deutsch MJ, Anagnostou O, Karatapanis S, Tiniakou E, Papatheodoridis GV, Georgiou E, Manesis E, Tzourmakliotis D, Archimandritis AJ. Liver Int. 2010 Nov;30(10):1454-60.

22.  Increased Arterial Stiffness and Impaired Endothelial Function in Nonalcoholic Fatty Liver Disease: A Pilot Study. Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, Aznaouridis K, Archimandritis A, Stefanadis C. Am J Hypertens 2010;23:1183-9.

23.  Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G,  Manesis EK, Mamalaki A, Archimandritis AJ. J Viral Hepat 2010;17:800-806.

24.  Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Manolakopoulos S, Manesis EK, Archimandritis AJ. J Clin Gastroenterol. 2010;44:e87-95.

25.  Incidence of hepatocellular carcinoma in a thalassemia unit. Fragatou S, Tsourveloudis I, Manesis EK. Hemoglobin 2010;34:221-226.

26.  Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Ann Rheum Dis 2010;69:1352-1355.

27.  The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary center. Giannousis I, Papatheodoridis GV, Deutsch M, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AJ. Eur J Epidemiol 2010;22:172-179.

28.  Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A. Hepatol Res 2009;39:972-978.

29.  Serum HCV RNA levels and HCV genotype do not affect insulin resistance in non-diabetic patients with chronic hepatitis C: a multicentre study. Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, Goulis I, Tzourmakliotis D, Akriviadis E, Manesis EK, Archimandritis AJ. Aliment Pharmacol Ther 2009;30:947-954.

30.  The natural history of chronic hepatitis B infection (Review). Manesis EK. Curr Hepat Rep 2009;8:10-17.

31.  Quantitative detection of the M204V HBV minor variants by amplification refractory mutation system real-time polymerase chain reaction (ARMS rt- PCR) combined with molecular beacon Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G, Manolakopoulos S, Beloukas A, Chryssoy S, Magiorkinis G, Sypsa V, Hatzakis A.. J Clin Microbiol 2009;47:2544-50.

32.  Hepatic parenchyma resection using stapling devices: peri-operative and long-term outcome. Delis SG, Bakoyiannis A, Karakaxas D, Athanassiou K, Tassopoulos N, Manesis E, Ketikoglou I, Papakostas P, Dervenis C. HPB (Oxford) 2009;11:38-44.

33.  Values for upper limit of normal should be given for liver enzymes in Wilson disease. Manesis EK. Hepatology 2009;49:1783-4 (Letter).

34.  Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B.Tsochatzis E, Papatheodoridis GV, Manolakopoulos S, Tiniakos DG, Manesis EK, Archimandritis AJ. Scand J Gastroenterol 2009;44:752-9.

35.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group. Gastroenterology 2009;136:1618-28.

36.  Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet. Greece cohort study.  Manesis EK, Papatheodoridis GV, Touloumi G, Karafoulidou A, Ketikoglou J, Kitis GE, Antoniou A, Kanatakis S, Koutsounas SJ, Vafiadis I; for the HEPNET. Greece Cohort Study. Aliment Pharmacol Ther 2009;29:1121-30.

37.  Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study. Mavrogiannaki A, Karamanos B, Manesis EK, Papatheodoridis GV, Koskinas J, Archimandritis AJ. J Viral Hepat 2009;16:430-6.

38.  Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. M Raptopoulou, G Papatheodoridis, A Antoniou, J Ketikoglou, D Tzourmakliotis, T Vasiliadis, N Manolaki, G Nikolopoulou, E Manesis, I Pierroutsakos. J Vir Hepat 2009;16:195-202.

39.  Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus  infection? Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ. Hepatology 2008;48:1451-1459.

40.  Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, Archimandritis AJ. Scand J Gastroenterol 2008;43:1128-36.

41.  Aetiology and outcome of acute hepatic failure in Greece: experience of two academic hospital centres. Koskinas J, Deutsch M, Kountouras D, Kostopanagiotou G, Arkadopoulos N, Smyrniotis V, Rapti I, Manesis E, Archimandritis A. Liver Int. 2008;28:821-827.

42.  Changes in liver enzymes activity in patients with rigor. Sevastos N, Manesis EK, Savvas S, Galiatsatos N, Papatheodoridis GV, Archimandritis AJ. Eur J Intern Med 2008;19:109-14.

43.  Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. J Viral Hepat. 2008;15:434-41.

44.  Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection. Hadziyannis E, Manesis E, Vassilopoulos D, Georgiou A, Archimandritis A. Clin Vaccine Immunol. 2008;15:385-7.

45.  Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis EK, Archimandritis AJ. Gut. 2008;57:500-6.

46.  Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Tsochatzis E, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Aliment Pharmacol Ther. 2008;27:80-89.

47.  Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Archimandritis AJ. Dig Liver Dis. 2007;39:936-942.

48.  Serum HBV DNA cut-off levels in HBeAg-negative chronic hepatitis B virus infection. Papatheodoridis GV, Manesis EK, Manolakopoulos S, Archimandritis A. (Letter). Hepatology 2007;46:606-7; author reply 607.

49.  Quantitative analysis of HDV-RNA and HBsAg serum levels in chronic delta hepatitis improves treatment monitoring. Manesis EK, Schina M, Le Gal F, Agelopoulou O, Kalligeros K, Arseniou V, Manolakopoulos S, Hadziyannis ES, Gault E, Koskinas J, Papatheodoridis G, Archimandritis A. Antivir Therapy 2007;12:381-388.

50.  Liver transplantation in Greek Patients: Epidemiological data, morbidity and mortality of 71 patients from a single center with 6 years mean follow-up. Tsochatzis E, Koskinas J, Manesis EK, Archimandritis EJ. Transplant Proc 2007;39:1505-1507.

51.  Acute ischemic hepatocellular injury due to a giant intahepatic hematoma. A rare complication of percutaneous liver biopsy. Tsochatzis E, Deutsch M, Zaphyropoulou R, Koskinas J, Manesis E. Eur J Intern Med 2007;18:339-41.

52.  First appearance of Crohn’s disease following infliximab treatment for spondylarthropathy. Tsochatzis E, Vassilopoulos D, Manesis EK, Papatheodoridis G, Bousiotou A, Hadziyannis E, Archimandritis AJ. Scand J Gastoenterol, 2007;42:784-785.

53.  Non-alcoholic fatty liver and cardiovascular disease: an emerging relationship. Baou K, Vlachopoulos C, Manesis E, Archimandritis A, Stefanadis C. Hellenic J Cardiol. 2007;48:37-41.

54.  Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Antivir Therapy 2007;12:73-82.

55.  Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon a/2b. Deutsch M, Manesis EK, Hadziyannis E, Cholongitas E, Vassilopoulos D,. Archimandritis AJ. Scand J Gastoenterol. 2007;42:408-409.

56.  Liver involvement in sickle cell vaso-occlusive crisis: Clinical, biochemical and haematological parameters. Koskinas J, Manesis EK, Zacharakis G,Galiatsatos N, Sevastos N, Archimandritis AJ. Scand J Gastoenterol 2007;42:499-507.

57.  Hepatic steatosis in genotype 4 chronic hepatitis C is mainly due to metabolic factors. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, Hadziyannis ES, Pandelidaki H, Zafiropoulou R, Koskinas J, Savvas S, Archimandritis AJ. Am J Gastroenterol 2007;102:634-41.

58.  HBeAg-negative  chronic  hepatitis  B:  From  obscurity  to  prominence (Editorial). Manesis EK. J Hepatol. 2006;45:344-346

59.  Diabetes mellitus in chronic hepatitis B and C: Prevalence and potential association with the extent of liver fibrosis. GV Papatheodoridis, Ν Chrysanthos, S Savvas, V Sevastianos, G Kafiri, K Petraki1, EK Manesis. J Vir Hepat 2006;13:303-310.

60.  Spontaneous bacterial peritonitis in cirrhotic patients: is prophylactic propanolol therapy beneficial? Cholongitas E, Papatheodoridis GV, Manesis EK, Burroughs AK, Archimandritis AJ. J Gastrenterol Hepatol 2006;21:581-587

61.  Pseudokalemia in serum: The phenomenon and its clinical magnitude.Sevastos N, Theodossiadis G, Efstathiou S, Papatheodoridis GV, Manesis EK, Archimandritis AJ. J Lab Clin Med 2006;147:139-144

62.  Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Chrysanthos NV, Papatheodoridis GV, Savvas S, Kafiri G, Petraki K, Manesis EK, Archimandritis AJ. Eur J Gastroenterol Hepatol 2006;18:389-396.

63.  A partially overlapping treatment course with Lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. EK. Manesis, G Papatheodoridis, S Hadziyannis Aliment Pharmacol Therap 2006;23:99-106.

64.  Cholestasis in acute stroke: An investigation on its prevalence and etiology. Sevastos N, Savvas S, Rafailidis PI, Manesis EK. Scand J Gastroenterol 2005;40:862-866.

65.  Long-term outcome of patients with HBeAg-negative chronic hepatitis B under nucleos(t)ide analogues maintenance therapy starting with lamivudine. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Tzourmakliotis D, Kitis G, Manesis EK, Hadziyannis S. Hepatology 2005;42:121-129.

66.  Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. Papatheodoridis GV, Petraki K,Chologitas E, Kanta E, Ketikoglou I, Manesis EK. J Vir Hepat 2005;12:199-206.

67.  Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Panagiotaki E, Tzetis M, Manolaki N, Loudianos G, Manesis EK, Arvanitakis S, Kanavakis. Am J Med Genetics 2004;131A:168-173.

68.  Painful peripheral neuropathy associated with voriconazole use. Tsiodras S, Zafiropoulou R, Kanta E, Deboneras C, Karandreas N, Manesis E. Arch Neurol 2005:62:144-146.

69.  Deep sinus aspergillosis after liver transplantation treated with a combination of caspofungin, voriconazole and local debridement. Tsiodras S, Zafiropoulou R, Giotakis J, Imbrios J, Antoniades A, Manesis EK. Transplant Infect Dis 2004;6:37-40.

70.  Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction in patients with hepatitis B e antigen-negative chronic hepatitis B. Manesis EK, Papatheodoridis GV, Sevastianos V, Chologitas E, Papaioannou C, Hadziyannis SJ. Am J Gastroenterol 2003;98:2261-2267.

71.  Naftidrofuryl induced liver injury (Letter to the Editor). Cholongitas E, Papatheodoridis G, Mavrogiannaki A, Manesis E. Am J Gastroenterol 2003;98:1448-1450.

72.  Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C (Letter to the Editor). Sevastianos B, Dourakis S, Manesis E. Am J Gastroenterol 2003; 98:706-707.

73.  Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Dig Dis 2002;20:284-288.

74.  Mesenteric venous thrombosis after transcatheter arterial chemoembolization for hepatocellular carcinoma (Letter to the Editor). Karagiannis S, Papatheodoridis G, Cholongitas E, Manesis EK. Am J Gastroenterology 2002;97:2685-2686.

75.  Serum HBV-DNA levels in inactive hepatitis B virus carriers (Letter to the Editor). Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Gastroenterology 2002;122:2092-2093.

76.  Small-bowel herniation under the infrarenal arterial conduit in a liver transplant recipient. Smyrniotis V, Arkadopoulos N, Kostopanagiotou G, Manesis Ε. Liver Transplant 2001;7:1002-1003.

77.  Interferon-alpha treatment and retreatment of Hepatitis B e antigen-negative chronic hepatitis B. Manesis EK, Hadziyannis SJ. Gastroenterology 2001;121:101-109.

78.  Induction interferon therapy in naïve patients with chronic hepatitis C: Increased end-treatment virological responses but absence of long-term benefit. Hadziyannis AS, Papaioannou C, Spanou F, Manesis EK, Hadziyannis SJ. Aliment Pharmacol Ther 2001;15:551-557.

79.  The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B. Papatheodoridis GV, Manesis EK, Hadziyannis SJ. J Hepatol 2001;34:306-313.

80.  Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: A randomised study. Hadziyannis S, Alexopoulou A, Papakonstandinou A, Petraki K, Manesis E. J Viral Hepat 2000;7:235-240.

81.  Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study. Hadziyannis SJ, Manesis EK, Papakonstantinou A. J Hepatol 1999;31:210-214.

82.  Neurovisual impairment: A frequent complication of alpha-interferon treatment in chronic viral hepatitis. Manesis EK, Moschos M, Brouzas D, Kotsiras J, Petrou K, Theodosiadis G, Hadziyannis S. Hepatology 1998;27:1421-1427. (See Editorial Hepatology 1998;27:1441-1442.)

83.  The effect of low-dose interferon treatment on visual evoked potentials. Moschos M, Manesis E, Panagakis E, Brouzas D, Hadziyannis S, Theodosiadis G. Documenta Ophthalmologica 1998;94:215-221.

84.  Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients. Manesis EK, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadziyannis SJ. Hepatology 1997;26:734-739.

85.  Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Hepatology 1997; 26:206-210.

86.  Computer image analysis of ultrasound images for discriminating and grading liver parenchyma disease employing a hierarchical decision tree scheme and the multilayer perception neural network classifier. Cavouras D, Kandarakis I, Theotokas I, Kanellopoulou E, Triandis D, Behrakis I, Manesis EK, Vafiadi I, Zoumboulis P. Stud Health Technol Inform 1997;43 Pt B: 522-526.

87.  Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomised, controlled trial. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis S. Hepatology 1995;21:1535-1542.

88.  Optic tract neuropathy complicating low-dose interferon treatment. Manesis EK, Petrou D, Brouzas D, Hadziyannis S. J Hepatol 1994;21:474-477.

89.  Splenomegaly in asymptomatic chronic carriers of hepatitis B and D viruses. Manesis E, Zoumboulis P, Georgiou S, Vardaka J, Hadziyannis S. Europ J Gastroenterol Hepatol 1994;6:793-796.

90.  Chronic hepatitis B: Therapeutic controversies and randomised controlled trials. Schalm SW, DeMan RA, Thomas HC, Jacyna M, Hadziyannis SJ, Manesis E. Gastroenterol Intern 1989;2:16-24.

91.  Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. Manesis ΕΚ, Cameron CH, Gregoriadis G. Bioch Soc Trans 1979;7: 678-680.

92.  Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. Manesis EK, Cameron CH, Gregoriadis G. FEBS Letters 1979;102:107-111.

93.  Incorporation of hepatitis B surface antigen (HBsAg) into liposomes. Manesis EK, Cameron CH, Gregoriadis G. Bioch Soc Trans 1978;6:925-628.

94.  Carcinoembryonic antigen in thyroid disease. Economidou J, Karacoulis P, Manousos O, Manesis E, Kydonakis A, Koutras D. J Clin Path 1977;30:878-880.

95.  Hepatitis B core antigen and antibody in primary liver cancer. Hadziyannis SJ, Karvountzis GG, Manesis EK, Merikas GE. Lancet 1975;i:418-419.

VIΙ.    ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ ΣΕ ΕΡΓΑΣΙΕΣ ΜΟΥ:

Συνολικός Αριθμός Ξένων Αναφορών: 3,913. (Collected from the website: https://www.researchgate.net/profile/Emanuel_Manesis/citations

την 30η Ιανουαρίου, 2020

Β. ΚΕΦΑΛΑΙΑ ΣΕ ΞΕΝΑ ΒΙΒΛΙΑ

1. Hepatitis D virus. Manesis EK, Katsoulidou AS. In: Molecular Detection of Human Viral Pathogens (Chapter 30). (Liu D, Editor). CRC Press, Taylor & Francis Publishers. London, UK. 2011, pp1073-88.

2. Cholinesterase  and  transaminase  levels  in  individuals  of  occupational pesticide exposure. Kafatos A, Manesis E, Tsatsakis A, Georgoulaki M, Makrigiannakis A, Koumantakis E. Aspects on Environmental Toxicology (Kotsaki V-P, Vafiadou AJ, Eds), Thessaloniki, Greece, 1995, p 213-215.

3. Liposomes: Interaction with the biological milieu and implications for their use in biology and medicine. Gregoriadis G, Kirby C, Manesis E, Clarke J, Davis C, Neerunjun C. Cell Biological Aspects of Disease (Deams WT, Burger EH, Afzelius BA, Eds), Leiden Univ. Press, The Hague, 1981, p. 259.

4. Liposomes  as  immunological  adjuvants  for  hepatitis  B  surface  antigen.

Gregoriadis G, Manesis EK. Liposomes in Immunobiology (Tom and Six, Eds), Elsevier/North-Holland Biomedical Press, New York, 1980, p. 271.

5. Surveillance of patients with chronic liver disease by serial testing for serum alpha-fetoprotein. Hadziyannis S, Karvountzis G, Manesis E, Dorn J, Merikas G. Carcino-Enbryonic Proteins, Vol II (Lehmann FG, Ed), Elsevier/ North-Holland Biomedical Press, 1979, p. 403.

6. Determination of serum folates by the use of competitive protein binding: Preliminary studies. Mantzos J, Gyftaki E, Alevizou V, Manesis E, Malamos B. Nuclearmedizin Radionuklide in der Haematologie (van Vaerenbergh P.M.et al., Eds), F.K. Schattauer Verlag, Stuttgart, 1973, p 68.